Introduction
▼ Eff ective and safe treatment of depressive, dysthymic, and dysphoric or mixed components of bipolar disorders remains among the most challenging problems in modern clinical psychopharmacology [ 1 , 2 ] . Overall, bipolar disorder patients in mid-course or from onset, treated by current community clinical standards, spend approximately half of the weeks of follow-up in symptomatic morbid states, and fully three-quarters of that morbidity is depressive [ 3 ] . Depressive components of bipolar disorder contribute importantly not only to long-term morbidity, but also to co-morbidity, disability, and excess mortality [ 1 , 2 ] . Despite the pressing need for improved treatments for depressive episodes and the frequent failure of ongoing preventive treatments, remarkably little research has been directed to the problem [ 2 ] . Expert treatment recommenda-tion antipsychotics, as well as lithium salts, specifi cally for treatment of acute bipolar depression. We hypothesized that these treatments would vary in the amount of information available as well as in apparent effi cacy based on data pooled across trials by meta-analytical methods using diff erent outcome measures.
Methods

▼
We performed a comprehensive literature search for reports on treatments for bipolar depression, focusing on randomized, controlled trials (RCTs) of mood-stabilizing anticonvulsants, second-generation antipsychotics, or lithium salts in acute major depressive episodes in patients diagnosed with type I or II BD. We carried out a systematic search [ 15 ] of several literature databases (PubMed, PsychInfo, EMBASE, and ClinicalTrials.gov). Search terms included various combinations of "anticonvulsants" (and names of individual agents; carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, valproate), "antipsychotics" (second-generation or atypical, and names of individual antipsychotics: amisulpride, aripiprazole, asenapine, iloperidone, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone); and "lithium" as well as "bipolar", "controlled", "depression", "efficacy", "randomized", "treatment", and "trial". In addition, we hand-searched citations in identifi ed reports and systematic reviews on this topic. Trial inclusion criteria were: [a] acute phase of major depressive episodes in type I or II BD diagnosed by standard, internationally accepted diagnostic criteria, [b] ≥ 18 patients/trial; [c] randomized treatment; [d] mood-stabilizing anticonvulsants, second-generation antipsychotics, or lithium salts as monotherapy; [e] placebo control ( ± other comparators); [f] double-blinded; [g] nominal trial duration ≥ 4 weeks. We excluded reports of studies concerning BD patients in episodes other than acute depression, trials involving add-on treatments, special populations (such as geriatric or pediatric patients, or those with known poor treatment responsiveness), and long-term studies of potential prophylactic eff ects. Abstracts of initially identifi ed reports were screened for possible relevance, and evaluated for meeting our a priori study criteria requirements by independent review of full texts by 2 investigators (VS and SS). As a secondary consideration, several trials of interest that were excluded from the primary meta-analyses due to methodological shortcomings, were considered separately; they included early, small, brief trials of lithium carbonate with crossover designs involving partial placebo controls, or comparisons of bipolar vs. unipolar major depression. We extracted data from included full reports, including the sex distribution and average age of subjects, treatments and doses, subjects per trial arm and number of collaborating sites, mean baseline depression ratings in each trial arm, and approximate average weeks of treatment. Clinical ratings involved changes in scores on a standardized depression symptom rating scale (usually Montgomery-Åsberg depression rating scale [MADRS] or Hamilton depression rating scale [HDRS] with 17 or 21 items). Outcomes were either improvement (and percentage change) in depression ratings or rates of achieving "response" (usually ≥ 50 % reduction of initial depression symptom ratings). We also recorded reported rates of prematurely dropping out of trials in each arm as well as reported rates of mood switching from depression into mania-like (hypomania, mania, or mixed manic depressive) states.
Analyses included random-eff ects meta-analyses for individual trials and with pooling for overall assessments and for specifi c agents. Outcomes involved pooled drug/placebo response rate ratios (RR), standardized mean diff erences (SMD, as Hedges' g statistic), or response rate diff erences (RD) used to estimate number-needed-to-treat (NNT, as 1/RD), all with 95 % confidence intervals (CI). In order to manage variance among outcome measures and its impact on rankings of apparent effi cacy, we averaged 3 rankings based on RR, SMD, and NNT for each trial, and noted ranking for all 10 agents included for analysis. Correlations were tested with bivariate linear regression ( r ) or non-parametric Spearman rank correlation ( r s ) methods. Potential covariates with SMD were assessed for at least suggestive associations ( p ≤ 0.10) in preliminary bivariate meta-regression analyses in preparation for multivariate meta-regression analysis. Averages are reported as mean ± standard deviation (SD), sometimes weighted by subject number. Changes in depression ratings were standardized by subject counts, and variance is reported as SD calculated or imputed from pooled SD from all trials [ 16 ] . 
Results
▼
Trials identifi ed
We identifi ed a total of 4 915 potentially relevant report titles at initial screening. Based on review of abstracts, 145 reports met eligibility criteria and were considered likely candidates for inclusion. Subsequent exclusions (121/145; 83.4 %) were as follows: [a] 97 (66.9 %) trials concerned BD patients in episodes other than acute depression, [b] 13 (8.97 %) were long-term studies of potential prophylactic eff ects; [c] 7 (4.83 %) involved add-on treatments, [d] 4 (2.76 %) involved special populations. An additional 19 trials did not meet inclusion criteria owing to design limitations but included fi ndings of interest and were considered for comment but not included in primary meta-analyses. In total, 24 trials met all inclusion/exclusion criteria and were included in the primary meta-analytical analyses ( • ▶ Table   1 ) [ 17 -38 ] . 2 included studies [ 18 , 27 ] had 3 arms comparing 2 diff erent drugs to placebo, and 2 others [ 24 , 29 ] reported on 2 independent trials of the same agents; each of these 4 separate drug-placebo comparisons was included as a separate trial. 5 trials lacked peer-reviewed publications (4 for lamotrigine, 1 for valproate), and their data were extracted from 2 pharmaceutical summary trial reports [ 32 , 33 ] and 5 reviews [ 34 -38 ] .
Trial characteristics
Overall meta-analysis included a total of 7 307 unique subjects (4 543 randomized to an active agent and 2 764 to placebo, adjusting placebo-treated subjects by 484 used in 2 comparisons [ 18 , 27 ] ); 16/20 trials (80.0 %) providing such information involved outpatients, and 4 (20.0 %) involved both hospitalized and ambulatory patients. The numbers of collaborating sites/ trial varied widely, from 1 to 110, and averaged 55. Proportions of bipolar disorder types varied, from all bipolar I in 86.5 % of trials, to all bipolar II participants in 1 trial with lamotrigine ( • ▶ Table 1 ). 10 treatments were tested, including: aripiprazole (2 trials, at 5-30 mg/day); carbamazepine (1 trial, at an average of 452 mg/day); lamotrigine (5 trials; mean dose 220 ± 48 mg/ day); lithium carbonate (1 trial; at 600-1 800 mg/day); lurasi-This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. all p ≤ 0.008), but do not yield identical rankings by apparent effi cacy. In order to deal with this variation among outcomes, we constructed rankings of apparent effi cacy (drug-placebo diff erences) of the 10 treatments for each of the 3 outcome measures and then averaged them. These averaged rankings by apparent effi cacy were as follow: olanzapine-fl uoxetine (mean rank = 1.67) > valproate (2.00) > carbamazepine (3.00) > lurasidone (4.00) > quetiapine (4.33) > olanzapine (6.67) > lamotrigine (7.00) > lithium (7.33) > ziprasidone (9.00) > aripiprazole (10.0). Of note, 5 of the 10 treatments tested did not show statistical superiority of active drug vs. placebo based on pooled SMD (aripiprazole, carbamazepine, lamotrigine, lithium, and ziprasidone), nor did 3 of these show separation by RR (all but carbamazepine and lamotrigine). In addition, 5/10 treatments (all of the preceding agents as well as olanzapine) yielded relatively unfavorable values of NNT ( ≥ 10). Lithium, aripiprazole, and ziprasidone were not superior to placebo based on all 3 outcome measures ( • ▶ Table 3 ). Findings concerning effi cacy measures for specifi c treatments are also illustrated in representative forest plots of SMD ( a ) and RR ( b ) values and their confi dence intervals ( • ▶ Fig. 1 , panels a and b ). It is important to emphasize that both in • ▶ Table 3 and • ▶ Fig. 1 , the 95 % CIs for most treatments overlap, indicting lack of signifi cant separation. These considerations and the small numbers of trials for most agents, indicate the need for caution in attempting to rank treatments by tested efficacy, based on the available data. Moreover, only lamotrigine, quetiapine, and valproate had more than 2 trials each, and 4 agents had only one (carbamazepine, lithium, lurasidone, and olanzapine + fl uoxetine; • ▶ Table 3 ).
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Covariates of eff ect size
The following factors lacked even suggestive covariance with SMD (all p > 0.10), as tested by bivariate meta-regression: 
Additional trials considered secondarily for comment
A total of 19 other trials in acute bipolar depression had relevant information but did not meet study criteria for inclusion in the primary meta-analyses. One trial of lamotrigine involving 410 bipolar I patients, without a placebo arm, found this anticonvulsant to be non-signifi cantly less eff ective than olanzapine + fl uoxetine (response rates: 60 vs. 68 %; p = 0.07) [ 39 ] . Another small trial with bipolar I and II disorder patients, also lacking placebo controls, found similarly small improvements (21 %; p = 0.78) with lamotrigine or citalopram added to mood stabilizers [ 40 ] .
In a third trial in 124 bipolar disorder subjects (68 % type I), after 8 weeks, lamotrigine added to lithium treatment was somewhat more eff ective than placebo (RR = 1.63 [CI: 1.05-2.53]; z = 2.17, p = 0.03) [ 41 ] . These fi ndings are inconclusive regarding the possible effi cacy of lamotrigine in acute bipolar depression. In earlier reviews, 6/9 uncontrolled trials of lithium suggested some clinical benefi t in bipolar depressed subjects, as did 8/9 placebo-controlled crossover trials [ 42 -44 ] , but found lithium to be inferior to a tricyclic antidepressant in 3/4 trials [ 45 ] . Several of these trials call for further consideration, even though they did not meet inclusion criteria for the primary meta-analyses of this study. We identifi ed 5 relatively small (approximately 16/ trial arm) and brief (10-28 days) trials that specifi cally considered hospitalized patients with BD depression and compared lithium treatment with placebo in various crossover designs, or compared patients identifi ed with BD vs. unipolar depression [ 46 -50 ] . Random-eff ects, meta-analytical summaries of the fi ndings indicated signifi cant superiority of lithium over placebo (n = 126 observations; RR = 4.85; CI: 1.54-15.3; z = 2.70, p = 0.007 [ 46 , 47 , 49 , 50 ] ) and in BD vs. unipolar depression (n = 155; RR = 2.40; CI: 1.66-3.48; z = 4.64, p = 0.005 [ 46 , 48 -50 ] ). These few trials underscore the paucity of research on eff ects of lithium in acute bipolar depression using adequate trial designs.
With carbamazepine , a small (N = 7), early crossover trial was inconclusive [ 51 ] . A second crossover trial involving 24 bipolar I or II disorder patents vs. 11 unipolar major depression cases found signifi cantly greater improvement in the bipolar cases (62 vs. 45 %) [ 52 ] . One trial without a placebo control found no diff erence between topiramate and bupropion in 38 depressed BD patients [ 53 ] . In 32 bipolar depressed patients (72 % type I) adding levetiracetam to various mood stabilizers yielded non-signifi cantly (12 %) worse outcomes than with placebo [ 54 ] . An open-label, uncontrolled trial of aripiprazole in 31 bipolar disorder patients was inconclusive as well as being associated with a substantial dropout rate (29 %), mainly owing to adverse eff ects [ 55 ] . Another uncontrolled, 84-day study of 30 bipolar disorder patients given aripiprazole (up to 40 mg/day) to augment other treatments also was inconclusive [ 56 ] . Finally, adding risperidone , paroxetine, or both to ongoing mood stabilizer treatment without placebo controls yielded similar, small benefi ts in small numbers of patients with treatmentresistant bipolar depression [ 57 ] .
Discussion
▼
Findings in this review of 24 randomized, placebo-controlled comparisons of non-antidepressant treatments for acute bipolar depression are consistent with other recent reviews of portions of this research topic in indicating both limited research and modest effi cacy of most treatments tested [ 8 -11 ] . Remarkably 
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Agents are ranked by observed drug/placebo response-rate ratios (RR) based on random-eff ects meta-analysis of individual trials reported in few such trials could be identifi ed, and very few treatments (only lamotrigine, quetiapine, and valproate) have been tested in more than one or 2 trials. We also found few additional, relevant trials, including of lithium, that could not be included in primary meta-analyses owing to methodological shortcomings [ 39 -57 ] . Eff ects of antidepressants in bipolar depression also have been reviewed extensively [ 14 , 58 ] . A noteworthy observation arising from this review is that rankings of specifi c treatments by apparent effi cacy varied with the outcome measure employed (raw % improvement, RR, SMD, or NNT; • ▶ Table 3 ), but diff erences tended to be minor ( • ▶ Fig. 1 ). (2) Ziprasidone (2) Lamotrigine (5) Lithium (1) Olanzapine (2) Carbamazepine (1) Lurasidone (1) Quetiapine (5) Valproate (4) (2) Ziprasidone (2) Lithium (1) Lamotrigine (5) Olanzapine (2) Quetiapine (5) Lurasidone (1) Carbamazepine (1) Valproate (4) Olanzapine+ Fluoxetine (1) Table 3 ). Drugs and their trial-counts (2) (3) (4) (5) in parentheses are on the y-axis. The symbols are sized in proportion to weight (based on trial counts) for each agent; horizontal bars are computed CIs; vertical solid lines are null values (SMD = 0.0; RR = 1.0). Eff ects of individual treatments are not clearly diff erentiated owing to overlapping CIs, but aripiprazole, lamotrigine, lithium, and ziprasidone were not signifi cantly superior to placebo by one or the other outcome measure.
owing to its strong association with weight gain and metabolic syndrome [ 59 ] . The evidence reviewed was remarkably inconsistent or unfavorable and poorly studied for several treatments for which better eff ects might have been expected ( • ▶ Table 2 , 3 ). Inconsistency is noteworthy for valproate and contrasts to its wide empirical application in various phases of bipolar disorder, including depression [ 37 , 38 ] . Similarly, lithium, too, is widely employed [ 2 , 60 , 61 ] , despite having virtually no research support of efficacy in acute bipolar depression ( • ▶ Table 3 ), despite some encouraging fi ndings in trials that did not meet study inclusion criteria. In addition, the performance of lamotrigine was uneven ( • ▶ Table 1 , 3 ), contrasting to its regulatory approval for longterm treatment of bipolar depressive and manic recurrences [ 2 ] . Moreover, lamotrigine usually is administered in slowing increasing doses to limit risks of dermatological reactions, making it diffi cult to employ in acute phases of bipolar disorder [ 2 ] . Of other agents considered, carbamazepine and lurasidone, with only one trial each, appear to be promising and require more study, and further study of lithium would be of interest. By comparison with the present fi ndings regarding eff ective non-antidepressant treatments (pooled RR for the most favorable treatments, lurasidone, olanzapine + fl uoxetine, quetiapine, and valproate: 1.47 [CI: 1.32-1.64]), a recent meta-analysis of 10 placebo-controlled trials of antidepressants in bipolar depression yielded a pooled RR of 1.43 (CI: 1.11-1.48) [ 10 ] . This outcome was unexpectedly similar to fi ndings in a comprehensive meta-analysis of 142 placebo-controlled trials of antidepressants in unipolar major depression (pooled RR = 1.42 [CI: 1.38-1.48]), the standard indication for antidepressants. This comparison suggests a lack of major diff erence in response to antidepressants in the 2 types of depressive illnesses [ 62 ] , or of clear superiority of anticonvulsants and antipsychotics vs. antidepressants in bipolar depression, despite their typical recommendation as options of fi rst-choice for this indication [ 7 ] . However, the place of antidepressants in the treatment of bipolar depression remains controversial and unresolved [ 2 , 14 , 57 ] . If some relatively favorable results reported here for non-antidepressants ( • ▶ Table 3 ) can be replicated consistently, it might be that some anticonvulsants and modern antipsychotics are somewhat superior to antidepressants for the treatment of bipolar depression. They also may be somewhat safer: rates of treatment-emergent mania-like states were uncommon in the trials reviewed and slightly lower with some active treatments than with placebo ( • ▶ Table 1 ).
A fi nal question requiring comment is why there are so few controlled trials of treatments for bipolar depression, despite the introduction of lithium carbonate, antipsychotics, and antidepressants into psychiatric therapeutics over a half-century ago. Antidepressants, though extraordinarily widely used to treat depressive phases of bipolar disorder [ 2 , 14 , 60 ] , tend to be avoided in the treatment of type I bipolar disorder patients in particular [ 63 , 64 ] . This tendency and the striking paucity of controlled trials in bipolar depression probably refl ect concerns about risks associated with excessive mood elevation -a concern no doubt shared by clinicians, patients, and potential pharmaceutical trial sponsors [ 63 , 64 ] . Such concerns appeared not to be relevant to treatment with most non-antidepressant agents, including olanzapine combined with fl uoxetine, as observed switch-rates were 3.7-4.7 %, albeit for relatively brief exposure times ( • ▶ Table 1 ). In addition, an emerging impression is that risks of mood-switching in bipolar disorder patients, including of type I, during antidepressant treatment, probably are much less than is widely assumed, and not much greater than the substantial spontaneous rates [ 65 ] . Another important basis for the paucity of treatment trials in bipolar depression may well be the highly questionable assumption that treatment effi cacy and safety in unipolar major depression syndrome can support generalization to all forms of depression [ 2 , 14 ] . Limitations of this study are profound, and refl ect the very limited numbers of reported, controlled trials of treatments for bipolar depression. If there is publication bias on this topic, it is likely to represent selection of relatively favorable trials, despite the generally modest fi ndings encountered [ 66 ] .
In conclusion, we found some evidence to support at least moderate effi cacy of some anticonvulsant and antipsychotic agents in acute bipolar depression, but with very few trials for most treatments, inconsistent performance for 2 of only 3 agents with multiple trials (lamotrigine and valproate, but not quetiapine), and inadequate testing of carbamazepine and lithium, in particular. This review underscores the remarkable conclusion that evidence regarding the possible value of non-antidepressant treatments for acute bipolar depression remains scarce and largely inconclusive -in contrast to the compelling clinical and public health nature of the problem, and prevalent recommendations of mood-altering anticonvulsants and modern antipsychotics as fi rst-line treatment options. The present observations strongly indicate the pressing need for additional treatment research in this severe, but surprisingly poorly studied disorder. In addition to adequate trials for typical cases of bipolar depression, more research is required to test treatment responses in cases of bipolar depression in types I and II bipolar disorder, types with sub-clinical hypomania ("spectrum"), and those with psychotic or mixed features, as well as to clarify the relative efficacy and safety of specifi c combinations and doses of treatments, and to establish safe and eff ective long-term treatments aimed at preventing recurrences of bipolar depression. Our general conclusion is that bipolar depression remains one of the most pressing, inadequately addressed problems in contemporary psychiatric therapeutics.
